Overview

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Status:
Active, not recruiting

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This study is designed to identify the best tolerated doses of [131]Iodine-MIBG and [90]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors. These drugs (131I-MIBG, 90Y-DOTATOC) are radioactive drugs, known as radionuclide therapy. Currently, the safest and best tolerated doses of these drugs (when combined together) is unknown.

Phase:

Early Phase 1

Details

Lead Sponsor:

David Bushnell

Collaborators:

Holden Comprehensive Cancer Center
National Cancer Institute (NCI)
National Institutes of Health (NIH)

Treatments:

Edotreotide
Octreotide